Uso terapéutico del cannabis

Publicaciones científicas

  1. Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial. (Annals Oncology 2011;22 febrero).
  2. Adverse effects of cannabis: inform psychologically vulnerable patients of the risk of serious, dose-dependent disorders. (Prescrire Int 2011;20:28-23).
  3. Bestard JA, Toth CC. An Open-Label Comparison of Nabilone and Gabapentin as Adjuvant Therapy or Monotherapy in the Management of Neuropathic Pain in Patients with Peripheral Neuropathy. (Pain Pract 2010;18 Noviembre).
  4. Parker LA, Rock E, Limebeer C. Regulation of nausea and vomiting by cannabinoids. (Br J Pharmacol 2010;22 Diciembre).
  5. Durán M, Pérez E, Abanades S, et al. Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. (Br J Clin Pharmacol 2010;70:656-663).
  6. Ware MA, Wang T, Shapiro S, et al. Smoked cannabis for neuropatic pain: a randomized controlled trial. (CMAJ 2010;340:800-4).
  7. Winstock AR, Ford C, Witton J. Assessment and management of cannabis use disorders in primary care. (BMJ 2010;340:800-4).
  8. Hoffmann DE, Weber E. Medical marijuana and the law.(N Engl J Med 2010;362:1453-7).
  9. Anònim. Medical Marijuana. The Medical Letter 2010;52:6-7.
  10. Anónimo. Dérivés du cannabis et douleur. Une petite place pour le delta9-tétrahydrocannabinol (THC) dans certaines scléroses en plaques. (Prescrire 2009;29:443-6).
  11. Zuurman L, Ippel AE, Moin E, van Gerven JMA. Biomarkers for the effects of cannabis and THC in healthy volunteers. (Br J Clin Pharmacol 2009;67:5-21).
  12. Iversen LL. The Science of Marijuana. (Br J Clin Pharmacol 2009;67:268).
  13. Blakemore C. Classification of cannabis and ecstasy in the UK. (BMJ 2009;338:490-1).
  14. Maldonado R. Cannabis. Beneficio y riesgo. (Med Clin (Barc) 2009;132:625-6).
  15. Rabanal Tornero M, Rams Pla N. Ús terapèutic dels cannabinoides: estudis Seguivex i Seguivex-Emesi. (BIT 2008;20:25-30).
  16. Wang T, Collet JP, Shapiro S, Ware MA. Adverse effects of medical cannabinoids: a Hampton T. Cannabislike drugs may hold key to treating pain while bypassing the brain. (JAMA 2008;300:1987).
  17. Márquez L, Abanades S, Andreu M. Sistema endocannabinoide e inflamación intestinal. (Med Clin (Barc) 2008;131:513-7).
  18. Anónimo. Patient with multiple sclerosis allowed to grow own cannabis. (BMJ 2008;337:716).
  19. Wang T, Collet JP, Shapiro S, Ware MA. Adverse effects of medical cannabinoids: a systematic review. (Can Med Assoc J 2008;178:1669-78).
  20. Madonado R. Sistema endocannabinoide: nuevas perspectivas en el tratamiento global de los factores de riesgo cardiometabólico. (Med Clin (Barc) 2008;130:615-22).
  21. Dyer O. UK tightens rules on cannabis despite advice not do to so. (BMJ 2008;336:1095).
  22. Mukamal KJ, MacLure M, Muller JE, Mittleman LA. An exploratory prospective study of marijuana use and mortality following acute myocardial infarction. (Am Heart J 2008;155:395-6).
  23. Thompson WM, Poulton R, Broadbent JM, Moffitt TE, Caspi A, Beck JD, Welch D, Hancox RJ. Cannabis smoking and periodontal disease among young adults. (JAMA 2008;299:525-31).
  24. Frank B, Serpell MG, Hughes J, Matthews JNS, Kapur D. Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. (BMJ 2008;336:199-201).
  25. Cohen SP. Cannabinoids for chronic pain. (BMJ 2008;336:167-8).

Darrera revisió: 24 Feb 2011 - 15:04
Copyright © 1999-2005 Fundació Institut Català de Farmacologia [http://www.icf.uab.es]